Last reviewed · How we verify
JMT101 injection
JMT101 injection is a monoclonal antibody targeting a specific protein to modulate the immune system.
JMT101 injection is a monoclonal antibody targeting a specific protein to modulate the immune system. Used for Treatment of moderate to severe rheumatoid arthritis.
At a glance
| Generic name | JMT101 injection |
|---|---|
| Also known as | Recombinant Humanized Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Injection, FOLFIRI(Irinotecan, Leucovorin Calcium, and Fluorouracil); mFOLFOX6((Oxaliplatin, Leucovorin Calcium, and Fluorouracil);, FOLFIRI; mFOLFOX6; Irinotecan;, Afatinib or Osimertinib |
| Sponsor | Shanghai JMT-Bio Inc. |
| Drug class | monoclonal antibody |
| Target | unknown |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
JMT101 injection works by binding to its target protein, thereby inhibiting its activity and modulating the immune response. This mechanism of action is thought to be beneficial in treating various immune-related disorders.
Approved indications
- Treatment of moderate to severe rheumatoid arthritis
Common side effects
- Injection site reactions
- Fatigue
- Headache
Key clinical trials
- SYS6002 Plus JMT101 and Enlonstobart Injection in Participants With HNSCC (PHASE2)
- JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer (PHASE2)
- A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations (PHASE3)
- JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations (PHASE2)
- JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JMT101 injection CI brief — competitive landscape report
- JMT101 injection updates RSS · CI watch RSS
- Shanghai JMT-Bio Inc. portfolio CI